Reimbursement decision for drotrecogin alfa, drug-eluting stents

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.375, 2002-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug-Eluting Stents

Heart Drug, Vol. 3, Iss. 4, 2004-02 ,pp. : 203-213

Karger

Access to resources Recommend Favorite

Decision models for assessing the cost effectiveness of drug-eluting stents

By Kong David F Eisenstein Eric L

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 965-974

Informa Healthcare

Access to resources Recommend Favorite

Drug-eluting stents: the safest option?

Reactions Weekly, Vol. 1, Iss. 1139, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Drug-eluting stents safe, effective

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Update on Sirolimus Drug-Eluting Stents

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 337-348

Bentham Science Publishers

Access to resources Recommend Favorite